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Abstract
Background: The receptor activator of NF-κB ligand (RANKL), a member of the TNF ligand superfamily, is known to
regulate bone metabolism. The expression of each component of the RANK/RANKL/osteoprotegerin (OPG) system in the
intervertebral disc (IVD) has not been examined in detail. The purposes of this study were to examine the expression of
the RANK/RANKL/OPG system and to evaluate the function of RANKL in the matrix metabolism of the rat IVD.
Methods: Sprague-Dawley, 12-week-old, male rats were used in this study. Anulus fibrosus (AF), nucleus pulposus (NP)
and cartilaginous endplate (CEP) cells isolated from dissected thoracolumbar discs were monolayer-cultured. RANK/
RANKL/OPG expression in rat IVDs was examined using real-time polymerase chain reaction (PCR) and
immunohistochemical analysis (cultured cells and IVD tissues). To examine the effect of interleukin-1β (IL-1β)
stimulation on the mRNA levels of RANK, RANKL and OPG, the cells were cultured with or without recombinant human
IL-1β (rhIL-1β). To evaluate the effect of RANKL on the mRNA expression of catabolic factors (IL-1β, matrix
metalloproteinase-3 (MMP-3) and MMP-13), the cells were cultured with RANKL in the presence or absence of rhIL-1β.
The immunohistochemical expression of this system was also evaluated using human IVD tissues with different grades
of degeneration.
Results: mRNA expression levels of RANK, RANKL, and OPG were clearly identified in AF, NP and CEP cells.
Immunoreactivity to RANK, RANKL and OPG was distributed in the cell membranes and/or cytoplasm of the three
types of cells. The mRNA level of RANKL was significantly upregulated by treatment with rhIL-1β of the three types of
cells. Treatment with RANKL without rhIL-1β did not induce significant effects on the mRNA expression of catabolic
factors by AF, NP and CEP cells. However, the expression was significantly upregulated by stimulation with RANKL in
the presence of rhIL-1β. There was a general trend for more RANK/RANKL/OPG-positive cells in human IVD tissues in
an advanced stage of degeneration compared to an early stage.
Conclusions: Our study showed the possibility that the RANK/RANKL/OPG system may play a part in the process of
intervertebral disc degeneration.
Keywords: Receptor activator of nuclear factor kappa B, Receptor activator of nuclear factor kappa B ligand,
Osteoprotegerin, Intervertebral disc, Cartilaginous endplate, Proinflammatory cytokine
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Background
The vertebral column complex consists of ventrally lo-
cated vertebral bodies and intervening intervertebral discs
(IVDs) that are closely attached by cartilaginous endplates
(CEPs). The IVD is composed of a central gelatinous nu-
cleus pulposus (NP) and a surrounding fibrous anulus
fibrosus (AF). Although the exact mechanism of IVD de-
generation remains unknown, the biochemical changes
typical of the degenerative IVD are known to include pro-
gressive decreases in proteoglycan and collagen type II
contents with subsequent dehydration and increased con-
tent of collagen type I, which leads to tissue fibrosis [1].
Interleukin-1 (IL-1) and tumor necrosis factor-alpha
(TNF-α) are thought to significantly affect matrix homeo-
stasis during IVD degeneration. An in vitro study showed
that IL-1 and TNF-α affect both anabolic and catabolic
pathways by stimulating the production of nitric oxide,
matrix metalloproteinases (MMPs) and aggrecanases and
finally result in the decrease of proteoglycan content by
both AF and NP cells [2–6].
Receptor activator of nuclear factor kappa B ligand
(RANKL) is a member of the TNF ligand superfamily that
is known to regulate bone metabolism [7, 8]. RANKL and
its receptor (RANK) have been shown to play crucial roles
in osteoclast differentiation and activation. The binding of
RANKL to RANK activates TNF receptor-associated fac-
tor (TRAF) 6, which stimulates the expression of proin-
flammatory cytokines through nuclear factor kappa B
(NF-κB) pathways [9]. Osteoprotegerin (OPG) is a soluble
decoy receptor for RANKL that prevents it from binding
to RANK. RANKL interacts with its receptor, which is
expressed on osteoclast precursors, to induce differenti-
ation and activation of osteoclasts [8]. The RANK-
RANKL signal has been associated with bone matrix ca-
tabolism by osteoclasts [10–12]. It has recently been re-
ported that the RANK/RANKL/OPG system is also
expressed by human articular cartilage [13, 14]; the rele-
vance of this system to the progression of osteoarthritis is
controversial. More recently, RANKL [15, 16] and OPG
[17] have been shown to be expressed by the human IVD,
and are considered to be associated with the progression
of IVD degeneration.
We hypothesized that expression of the RANK/
RANKL/OPG system is associated with IVD degener-
ation. The purposes of this study were: (1) to examine
the mRNA and immunohistochemical expression of the
RANK/RANKL/OPG system in the rat IVD, including
the CEP; (2) to examine the expression of the RANK/
RANKL/OPG system under stimulation by IL-1β; (3) to
evaluate the effect of RANKL on the expression of cata-
bolic factors with and without proinflammatory stimula-
tion and (4) to examine the expression of the RANK/
RANKL/OPG system in the human IVD with different
stages of degeneration.
Methods
Sprague-Dawley, 12-week-old, male rats were used in this
study, with institutional animal care committee approval.
Cell preparation and culture conditions
IVDs were harvested from 10 rat spines for each series
of cell culture experiments. The AF, NP and CEP were
carefully dissected from thoracolumbar discs. IVD cells
were isolated by sequential enzyme digestion with 0.4%
Pronase (Calbiochem, La Jolla, CA, USA) for 1 hour
(AF, CEP) or 30 minutes (NP), followed by 0.025% Colla-
genase P (Roche Applied Science, Mannheim, Germany)
for 3 hours (AF), 30 minutes (NP) or 1 hour (CEP) in a
5% CO2, 95% air incubator at 37 °C. Following enzyme
digestion, the suspension was filtered through a 40-
μm mesh (BD Falcon, Franklin Lakes, NJ, USA) for AF
cells or 70-μm mesh for NP and CEP cells. The filtered
cells were first washed with Dulbecco’s modified Eagle’s
medium and Ham’s F-12 medium (DMEM/F12; Gibco,
Palo Alto, CA, USA) and primary culture was begun.
Isolated cells were cultured in monolayer in 4-chamber
slides (BD Falcon) for immunohistochemical analysis at
1.4 × 104 cells/mL or 6-well tissue culture plates (BD Fal-
con) at 4.0 × 104 cells/mL, with 5% CO2, 95% air in
complete medium (DMEM/F12 containing 10% fetal bo-
vine serum (FBS; Biological Industries, Kibbutz Beit
Haemek, Israel), 25 μg/mL ascorbic acid (Sigma-Aldrich)
and 50 μg/mL gentamicin (Gibco)]. The medium was
changed every third day. Primary cultured cells (in cu-
mulative population doublings) were used in all the ex-
periments conducted in this study.
The effect of IL-1β stimulation on mRNA levels of RANK/
RANKL/OPG
Following 7 (AF, CEP) or 10 days (NP) of monolayer
pre-culture, the AF, NP or CEP cells were cultured in
serum-free medium for 24 hours. The cells were then
cultured with or without recombinant human IL-1β
(rhIL-1β; R&D Systems, Minneapolis, MN, USA) at 0.01,
0.1, 1.0 or 10 ng/mL in DMEM/F12 containing 0.3%
FBS, for an additional 24 hours.
The effect of RANKL on the mRNA expression of anabolic
and catabolic factors with or without IL-1β
After 7 (AF, CEP) or 10 days (NP) of monolayer pre-
culture, all the cells were cultured in serum-free
medium for 24 hours. The cells were then cultured in
DMEM/F12 containing 0.3% FBS, for an additional
24 hours with or without 10 or 100 ng/mL recombin-
ant human RANKL (rhRANKL; Wako Pure Chemical,
Osaka, Japan) in the presence or absence of rhIL-1β
(1.0 ng/mL).
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RNA isolation
Total cellular RNA was extracted from rat AF, NP and
CEP cells in monolayer culture using Isogen (Nippon
Gene, Toyama, Japan), according to the manufacturer’s
instructions. Total RNA was reverse-transcribed using
the first-strand Complementary DNA (cDNA) synthesis
kit (Roche Applied Science) with the DNA thermal cy-
cler (Veriti; Applied Biosystems, Foster City, CA, USA),
according to the manufacturer’s protocol.
Quantitative real-time polymerase chain reaction (PCR)
Following treatment with IL-1β and/or RANKL, the re-
sultant cDNA (in triplicate) was amplified for the follow-
ing target genes: RANK, RANKL, OPG, IL-1β, MMP-3
and MMP-13. Inventoried (ready-made) primers corre-
sponding to target genes were used in this study (Table 1:
TaqMan Gene Expression Assays, Applied Biosystems).
Real-time PCR was performed using the ABI PRISM
7000 Sequence Detection System (Applied Biosystems).
PCRs were carried out in duplicate with 1 cycle at 50 °C
for 2 minutes, 1 cycle at 95 °C for 10 minutes and 40 cy-
cles at 95 °C for 15 seconds and at 60 °C for 1 minute.
The assay was calibrated using 18S ribosomal RNA
(rRNA) as an internal control.
Immunohistochemical analysis of rat IVD cells
Rat AF, NP and CEP cells were monolayer-cultured on 4-
chamber slides for 4 days. The cells were fixed in 4% para-
formaldehyde, treated with a blocking solution containing
10% skim milk, and permeabilized in 0.1% Triton X-100
(NACALAI TESQUE Inc., Kyoto, Japan), then incubated
with anti-RANK (ab12008, 1:500; Abcam, Cambridge,
UK), anti-RANKL (ab9957, 1:500; Abcam) or anti-OPG
(sc- 8468, 1:50; Santa Cruz Biotechnology, Santa Cruz,
CA, USA) antibodies overnight at room temperature. For
isotype control, the cells were incubated with mouse
isotype-matched immunoglobulin G (IgG; Dako, Glostrup,
Denmark) instead of the primary antibodies. Secondary
Alexa 488-conjugated anti-mouse IgG (1:400; Molecular
Probes, Eugene, OR, USA), anti-rabbit IgG or anti-goat
IgG antibodies were applied for 3 hours at room
temperature. The nuclei were stained with propidium iod-
ide (1:100; Molecular Probes) for 5 minutes. The cells
were then cover-slipped with Vectashield mounting
medium (Vector Laboratories, Burlingame, CA, USA).
Samples were imaged using confocal laser scanning mi-
croscopy (Fluoview FV1000; Olympus, Tokyo, Japan).
Immunohistochemical analysis of normal rat IVD tissues
Rat lumbar spines (vertebrae L1-L6 (n = 2)) were removed
and fixed in 4% paraformaldehyde, followed by decalcifica-
tion in 30% ethylenediaminetetraacetic acid for 28 days.
The samples were embedded in paraffin and serial 5-μm
cross-sections were processed and stained with safranin-O/
hematoxylin and eosin (safranin-O/HE) for immunohisto-
chemical analysis. After blocking endogenous peroxidase
activity, the sections for RANK and RANKL were heated
with 0.01 M citrated buffer (pH 6.0) and those for OPG
were treated with proteinase K (pH 8.0). The sections were
then incubated overnight at room temperature with the pri-
mary antibodies used in the monolayer culture study. The
appropriate rabbit IgG (Dako), mouse IgG or goat IgG was
used as the isotype control. The sections were incubated
with the appropriate anti-mouse, anti-rabbit or anti-goat
horseradish peroxidase (HRP)-conjugated secondary anti-
body (Dako). Peroxidase activity was detected with 3, 3-
diaminobenzidine tetrahydrochloride (DAB; Dojindo,
Kumamoto, Japan). The sections were counterstained in
Mayer’s hematoxylin.
Immunohistochemical analysis of human IVD tissues
Institutional Review Board (IRB) approval was obtained
for this study. Human IVD tissues were obtained from
spine surgery with informed consent from all patients.
The samples were divided into different stages of degrad-
ation according to Pfirrmann’s magnetic resonance im-
aging (MRI) classification [18]: grade 2 (n = 4); grade 3 (n
= 11); and grade 4 (n = 13). Grades 2 and 3 were defined
as early degenerated tissue, while grade 4 was defined as
advanced degenerated tissue. The samples were embedded
in paraffin, and serial 5-μm sections were used for
safranin-O/HE staining and immunohistochemical ana-
lysis as described. Each sample was divided into three
areas: nucleus pulposus (NP), inner annulus fibrosis (iAF),
and outer annulus fibrosis (oAF). With the Cell Counter
plugin in Image J (National Institutes of Health), the per-
centages of positive staining in cells were quantified for
each antibody by determining the mean percentage of
immunopositive cells from five fields of microscopic im-
ages per sample at × 400 magnification (Fig. 6a).
Statistical analysis
The data are expressed as the mean ± standard error of
three independent experiments. The data were analyzed
Table 1 Primers for real-time polymerase chain reaction (PCR)
Genes Assay IDa Size (bp)
RANK Rn04340164_m1 63
RANKL Rn00589289_m1 69
OPG Rn00563499_m1 75
IL-1β Rn00580432_m1 74
MMP-3 Rn00591740_m1 67
MMP-13 Rn01448192_m1 93
18S rRNA Hs99999901_s1 187
RANK receptor activator of nuclear factor kappa, RANKL rank ligand, OPG
osteoprotegerin, MMP matrix metalloproteinase, rRNA ribosomal RNA. aTaqMan
Gene Expression Assays (Applied Biosystems)
Takegami et al. Arthritis Research & Therapy  (2017) 19:121 Page 3 of 10
by one-way analysis of variance (ANOVA) using the
between-subject factors for the different experimental
groups. The post hoc analyses were performed using the
Fisher protected least significant difference (PLSD) test.
The evaluation of statistical differences between the
groups was determined using the unpaired Student's t
test. Significance was accepted at p < 0.05.
Results
Immunohistochemical analysis of normal rat IVD tissues
Every component of the RANK/RANKL/OPG system was
identified in AF, NP and CEP tissues of normal IVDs from
12-week-old rats (Fig. 1). Intense immunoreactivity to
RANK, RANKL and OPG was found particularly in the
NP and CEP. Cells immunoreactive to RANK, RANKL
and OPG were also identified in the AF, but showed less
positive immunoreactivity than in the NP. No immunore-
activity was found in isotype controls (rabbit IgG).
Fluorescent immunohistochemical analysis of rat IVD cells
Immunoreactivity to RANK, RANKL and OPG was
clearly identified in monolayer cultures of rat AF, NP
and CEP cells (Fig. 2). Confocal images revealed that
immunoreactivity to RANK was primarily found in
cell membranes and cytoplasm of the three types of
cells. The expression of RANKL was distributed in
granules in the cytoplasm of all the cells. OPG immu-
noreactivity was found in a spot-like distribution in
the cytoplasm of all the cells. No immunoreactivity
was found in the isotype controls.
Detection of mRNA expression of RANK/RANKL/OPG by rat
IVD and CEP cells
The expression levels of RANK, RANKL and OPG
were quantified using real-time PCR. mRNA expres-
sion levels of RANK, RANKL and OPG were clearly
seen in AF, NP and CEP cells (Fig. 3). A significant,
but mild increase in the mRNA expression of RANKL
was found in CEP cells, compared to that in AF and
NP cells (p < 0.01). However, there were no significant
differences in the expression levels of RANK and
OPG among the three types of cells (relative expres-
sion in the NP (vs. the AF): RANK 2.26 ± 0.91,
RANKL 1.01 ± 0.37, OPG 1.34 ± 0.21; expression in the
CEP (vs. the AF): RANK 4.27 ± 1.88, RANKL 2.54 ±
0.58, OPG 1.11 ± 0.39).
The effect of IL-1β stimulation on mRNA levels of RANK/
RANKL/OPG
The mRNA level of RANKL was significantly upregu-
lated by treatment with IL-1β (10 ng/mL) (relative
expression (vs. control): RANKL in the AF 20.92 ±
5.12, p < 0.01; RANKL in the NP 40.16 ± 14.13, p <
0.01; RANKL in the CEP 45.33 ± 25.43, p < 0.05)
(Fig. 4b, e, h). Stimulation by IL-1β (10 ng/mL) in-
duced a significant increase in the mRNA expression
of RANK and OPG in NP cells (relative expression
(vs. control): RANK 2.66 ± 0.35, p < 0.01; OPG 3.33 ±
1.07, p < 0.01) (Fig. 4d, f ). The mRNA expression
levels of RANK and OPG in both AF and CEP cells
did not significantly differ with stimulation by IL-1β
(Fig. 4a, c, g, i).
NP
AF
RANK RANKL OPG
CEP
A B
FE G
DC
JI K L
H
Isotype
Fig. 1 Immunohistochemical staining for receptor activator of nuclear factor kappa B (RANK)/RANK ligand (RANKL)/osteoprotegerin (OPG) in normal rat
intervertebral disc (IVD) tissues (anulus fibrosus (AF) (a-d); nucleus pulposus (NP) (e-h); cartilaginous endplate (CEP) (i-l)). Paraffin-embedded sections of
rat IVDs (12-week-old male rats (n = 2)) were stained with mouse monoclonal anti-RANK antibody (a, e, i), rabbit polyclonal anti-RANKL antibody (b, f,
j), or goat polyclonal anti-OPG antibody (c, g, k). Isotype controls are shown in d, h and l. Scale bar 10 μm
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The effect of RANKL on the mRNA expression of
proinflammatory cytokines and proteolytic enzymes with
or without IL-1β stimulation
The mRNA expression levels of IL-1β, MMP-3, and MMP-
13 in rat AF, NP and CEP cells were quantified using real-
time PCR (Fig. 5). Treatment with RANKL in the absence
of rhIL-1β did not produce a significant effect on the
mRNA expression of IL-1β, MMP-3 and MMP-13 by AF
cells (relative expression: RANKL 100 ng/mL (vs. RANKL
0 ng/mL), IL-1β 0.89, p = 0.91; MMP-3 1.45, p = 0.98;
MMP-13 2.92, p = 0.98) (Fig. 5a–c). However, the mRNA
expression of IL-1β, MMP-3 and MMP-13 in AF cells was
significantly upregulated by stimulation of RANKL with IL-
1β (1.0 ng/mL) (relative expression: RANKL 100 ng/ml +
IL-1β (vs. RANKL 0 ng/mL+ IL-1β), IL-1β 2.86, p < 0.01;
MMP-3 3.91, p < 0.05;MMP-13 3.66, p < 0.01) (Fig. 5a–c).
B
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Fig. 2 Immunohistochemical staining for receptor activator of nuclear factor kappa B (RANK)/RANK ligand (RANKL)/osteoprotegerin (OPG) in
cultured rat anulus fibrosus (AF), nucleus pulposus (NP) and cartilaginous endplate (CEP) cells. All the cells were cultured in monolayer for 3 days:
a-d AF; e-h NP; i-l CEP. d, h, l Isotype controls. Samples were imaged using confocal microscopy. Immunoreactivity (green) is clearly seen in the
AF, NP and CEP cells. Nuclei are stained with propidium iodide (red). Scale bar 10 μm
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Fig. 3 Detection of mRNA expression of receptor activator of nuclear factor kappa B (RANK)/RANK ligand (RANKL)/osteoprotegerin (OPG) in rat
anulus fibrosus (AF), nucleus pulposus (NP) and cartilaginous endplate (CEP) cells. Significantly higher mRNA expression levels of RANKL were
found in CEP cells than those in AF and NP cells; *p < 0.05. There were no significant differences in expression levels of RANK and OPG among AF,
NP and CEP cells
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Stimulation of NP cells by RANKL without rhIL-1β
stimulation did not produce significant upregulation
of mRNA expression of IL-1β, MMP-3 and MMP-13
(relative expression: RANKL 100 ng/ml (vs. RANKL
0 ng/mL), IL-1β 0.83, p = 0.96; MMP-3 0.40, p = 0.98;
MMP-13 1.41, p = 0.91) (Fig. 5d–f ). The mRNA ex-
pression of IL-1β, MMP-3 and MMP-13 by NP cells
was significantly upregulated by stimulation with
RANKL and rhIL-1β (1 ng/mL) (relative expression:
RANKL 100 ng/mL + IL-1β (vs. RANKL 0 ng/mL +
IL-1β), IL-1β 4.79, p < 0.01; MMP-3 1.38, p < 0.05;
MMP-13 2.15, p < 0.01) (Fig. 5d-f ).
Similarly, stimulation of CEP cells by RANKL with-
out rhIL-1β stimulation did not induce significant
changes in mRNA expression of IL-1β, MMP-3 and
MMP-13 (relative expression: RANKL 100 ng/mL (vs.
RANKL 0 ng/mL); IL-1β 0.81, p = 0.95; MMP-3 0.50,
p = 0.99; MMP-13 0.56, p = 0.91) (Fig. 5g–i). The
mRNA expression of IL-1β, MMP-3 and MMP-13 by
CEP cells was significantly upregulated by stimulation
with RANKL and rhIL-1β (1 ng/mL) (relative expres-
sion: RANKL 100 ng/mL + IL-1β (vs. RANKL 0 ng/
mL + IL-1β); IL-1β 5.68, p < 0.05; MMP-3 7.49, p <
0.01; MMP-13 2.54, p < 0.05) (Fig. 5g–i).
Expression of the RANK/RANKL/OPG system in human
IVD tissues with different stages of degeneration
The total percentage of cells immunopositive for RANK
was significantly higher in grade 4 tissues compared to
that in grade 2 tissues (mean percentage of immuroreac-
tive cells: grade 2, 77.2 ± 11.0; grade 3, 82.1 ± 9.2; grade
4, 87.5 ± 6.7; p < 0.05 vs. grade 2) (Fig. 6b). The percent-
age of cells with a positive stain in the NP region was
significantly higher in grade 4 tissues compared to that
in grade 3 tissues (p < 0.05). There were no significant
differences between the different grades of degeneration
in the iAF and oAF regions.
The total percentage of cells immunoreactive for
RANKL was significantly higher in grade 4 tissues com-
pared to those in grade 2 and grade 3 tissues (mean per-
centage of immuroreactive cells: grade 2, 51.9 ± 11.8;
grade 3, 59.2 ± 12.1; grade 4, 80.4 ± 11.5; p < 0.01 vs.
grade 2 and grade 3, respectively, Fig 6b). Grade 3 and
grade 4 tissues had significantly higher percentages of
cells immunoreactive for RANKL in the oAF region than
grade 2 tissues (p < 0.05, respectively). In the iAF region,
grade 4 tissues had a significantly higher percentage of
cells with a positive stain than those in grade 2 and
grade 3 tissues (p < 0.01, respectively). The percentage of
A D G
B E H
C F I
Fig. 4 The effect of interleukin-1beta (IL-1β) on mRNA levels of receptor activator of nuclear factor kappa B (RANK)/RANK ligand (RANKL)/osteoprotegerin
(OPG) by rat anulus fibrosus (AF), nucleus pulposus (NP) and cartilaginous endplate (CEP) cells. The mRNA expression levels of RANK (a, d, g), RANKL (b, e, h),
and OPG (c, f, i) by AF (a-c), NP (d-f) and CEP (g-i) cells were quantified by real-time polymerase chain reaction. Stimulation of rat NP cells with IL-1β at
10 ng/mL significantly increased mRNA expression of RANK, RANKL and OPG compared with the control group. Stimulation of rat AF and CEP cells with IL-
1β at 10 ng/mL significantly increased mRNA expression of RANKL compared with the control group. No significant changes in mRNA expression levels of
RANK and OPG in AF and CEP cells were detected from treatment with IL-1β: *p< 0.05, **p< 0.01 vs. control. FBS fetal bovine serum
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Fig. 5 The effect of receptor activator of nuclear factor kappa B ligand (RANKL) on the mRNA expression of proinflammatory cytokines and proteolytic
enzymes with or without recombinant human interleukin-1beta (rhIL-1β) stimulation. The mRNA expression levels of IL-1β (a, d, g), matrix metalloproteinase
(MMP) -3 (b, e, h), and MMP-13 (c, f, i) by the anulus fibrosus (AF) (a-c), nucleus pulposus (NP) (d-f) and cartilaginous endplate (CEP) (g-i) cells were
quantified by real-time polymerase chain reaction. Treatment with RANKL in the absence of rhIL-1β did not induce a significant effect on the mRNA
expression of IL-1β, MMP-3 or MMP-13 in AF, NP and CEP cells. However, the mRNA expression of IL-1β, MMP-3 and MMP-13 in AF, NP and CEP cells was sig-
nificantly upregulated by the stimulation of RANKL with rhIL-1β (1.0 ng/mL): *p< 0.05, **p< 0.01 vs. RANKL 0 ng/mL + IL-1β 1 ng/mL
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Fig. 6 Immunohistochemical staining for the receptor activator of nuclear factor kappa B (RANK)/RANK ligand (RANKL)/osteoprotegerin (OPG) system in
human intervertebral disc (IVD) tissues. a Paraffin-embedded sections of human IVD tissues (outer anulus fibrosus (oAF) (A-C); inner anulus fibrosus (iAF)
(D-F); nucleus pulposus (NP) (G-I) were stained with mouse monoclonal anti-RANK antibody (A, D, G), rabbit polyclonal anti-RANKL antibody (B, E, H) or goat
polyclonal anti-OPG antibody (C, F, I). J, L Isotype controls. Scale bar 20 μm. b Percentage of cells immunopositive for RANK, RANKL and OPG in different
grades of disc degeneration: *p< 0.05, **p< 0.01
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positive stains in the NP region was significantly greater
in grade 4 than in grade 3 tissues (p < 0.05).
The total percentage of cells with positive staining for
OPG was significantly higher in grade 4 tissues compared
to that in grade 3 tissues (mean percentage of immuror-
eactive cells: grade 2, 54.9 ± 13.5; grade 3, 41.7 ± 26.5;
grade 4, 61.1 ± 16.1; p < 0.05 vs. grade 3, Fig. 6b). Within
the total amount of immunoreactive cells, grade 4 tissues
had a significantly greater percentage of positively stained
cells compared to grade 3 tissues in the NP region (p <
0.05). There were no significant differences between the
different grades of tissue in the iAF and oAF regions.
Discussion
The present study demonstrated that expression of the
RANK/RANKL/OPG system was confirmed both at
mRNA and protein levels in the rat IVD, including the
in CEP. Quantitative mRNA analysis identified a similar
mRNA expression level of the RANK/RANKL/OPG sys-
tem by AF, NP and CEP cells. To examine the effect of
the RANK/RANKL/OPG system on matrix metabolism,
exogenous IL-1β and/or RANKL were administered to
rat IVD and CEP cells. The expression of RANKL was
regulated by stimulation with IL-1β by rat AF, NP and
CEP cells. Although catabolic factors, such as IL-1β,
MMP-3 and MMP-13, were not stimulated by RANKL
alone, the gene expression was significantly enhanced by
stimulation with RANKL in the presence of IL-1β.
An immunohistochemical analysis recently reported by
Mackiewicz et al. [15] showed that RANK, RANKL and
OPG are expressed in degenerated human AF tissue. Gru-
ber et al. [16] report that the gene expression of RANKL
in the human disc is significantly higher in degenerated
IVDs compared to normal IVDs. Increased expression of
OPG has also been identified in degenerated human IVD
tissues compared to healthy IVDs [17]. The results of
these previous studies and our immunohistochemical hu-
man IVD study suggest that the expression of the RANK/
RANKL/OPG system identified in human IVDs may be
associated with the progression of disc degeneration. The
results of the present study demonstrate, for the first time,
that each component of the RANK/RANKL/OPG system
was constitutively expressed in normal rat AF and NP cells
both at mRNA and protein levels, and also in those tissues
at the protein level.
In this study, to mimic the micro-environment that may
occur in degenerated IVDs [2], rat AF and NP cells were
cultured in the presence of IL-1β. The mRNA expression
of RANKL was significantly and dose-dependently upregu-
lated by both rat AF and NP cells by stimulation with IL-
1β. This result supports a previous report showing that
the gene expression of RANKL was higher in degenerated
discs than in normal discs [16]. Importantly, in this study,
the response to IL-1β stimulation was greater in NP cells
than in AF cells. On the other hand, IL-1β produced sig-
nificant, but minor, stimulation of the gene expression of
RANK and OPG by NP cells, but not AF cells. These re-
sults indicate that, among the three components of the
RANK/RANKL/OPG system, the expression of RANKL
was most strongly stimulated by IL-1β.
Proinflammatory cytokines, such as TNF-α, IL-1β and
IL-6, have been implicated in the pathogenesis of inflamma-
tory osteolysis (osteoclastgenesis), both directly and indir-
ectly [19]. These proinflammatory cytokines markedly
stimulate osteoblasts or stromal cells to produce RANKL,
with a minor effect on the release of OPG [19–22]. These
molecular changes are considered to be among the factors
leading to the imbalance of homeostasis of the bone matrix
in inflammatory bone-erosive diseases. Interestingly, these
responses of proinflammatory cytokines on the expression
of RANKL and/or OPG by osteoblasts were similar to those
on rat IVD cells shown in this study. This suggests that
proinflammatory cytokines may have a role in regulating
the balance between the expression of RANKL and OPG,
not only by the osteoblastic phenotype, but also by the
chondrogenic phenotype, including IVD cells.
Although our study showed no, or only minor, effects
of IL-1β on the expression of OPG by rat IVD cells,
other studies have reported positive correlation between
the grade of degeneration of human IVD tissues and
OPG levels in IVD tissues [17] and serum [23]. Micro-
environmental differences between human IVD tissues
and rat cells cultured in vitro might also be responsible
for this discrepancy between our study and others.
To examine the effect of RANKL on matrix metabolism,
rat IVD cells were treated with exogenous RANKL. The
gene expression of catabolic molecules, such as IL-1β,
MMP-3 and MMP-13 by both rat AF and NP cells was
not stimulated by RANKL alone. Similar results have been
reported from previous studies on human articular chon-
drocytes [13, 14] showing that exogenous RANKL does
not activate NF-κ B or induce the expression of genes en-
coding catabolic mediators. Kwan Tat et al. [14] specu-
lated that a low percentage of RANK-positive sub-
populations in human articular chondrocytes may be re-
lated to the mechanism for this lack of effect by RANKL
stimulation. Multiple isoforms of RANK truncated in their
intracellular domain have been reported [24]. One of these
isoforms of RANK (TNFRSE11A_e5a) was recently found
to have low affinity for the RANKL capable of activating
NF-κB [25]. These previous studies suggest that the pro-
tein level and/or the character of isoform types may also
affect RANKL signaling by rat IVD cells.
In contrast, the results of our study showed that the
mRNA expression of IL-1β, MMP-3 and MMP-13 by both
rat AF and NP cells was significantly upregulated by ex-
ogenous RANKL in the presence of IL-1β. This result led
us to speculate that proinflammatory cytokines, such as IL-
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1β, may have the potential to activate the RANKL signaling
pathway by affecting the protein level and/or the character
of isoform types of RANK, which is associated with the NF-
κB signaling pathway. Although RANKL stimulation alone
did not influence the expression of catabolic factors in nor-
mal IVDs, these catabolic factors may be accelerated by
stimulation with RANKL in the proinflammatory cytokine-
rich micro-environment found in degenerating IVDs.
The CEP is a layer of hyaline cartilage found between
IVD tissues and the vertebral body, which plays an im-
portant role in regulating nutrient transport and meta-
bolic exchange [26]. The biochemical characteristics of
the extracellular matrix of the CEP are similar to those
of IVD tissues, and during IVD degeneration, the CEP
also shows degenerative changes, including deceases in
proteoglycan and collagen content and upregulation of
proinflammatory cytokines and proteolytic enzymes,
hallmarks similar to those of IVD degeneration [27, 28].
Therefore, we additionally examined the expression of
the RANK/RANKL/OPG system in the rat CEP, and also
evaluated the effect of RANKL and rhIL-1β on the
matrix metabolism of rat CEP cells. mRNA and protein
expression of the RANK/RANKL/OPG system was also
found in rat CEP cells, and the response of rhIL-1β and/
or RANKL stimulation on rat CEP cells showed a ten-
dency similar to that found in rat IVD cells.
To further test the hypothesis, we have additionally ex-
amined the expression of the RANK/RANKL/OPG system
in human IVD tissues with different stages of degener-
ation. The present study showed there was a general trend
for a higher presence of RANK/RANKL/OPG-positive
cells in human IVD tissues in an advanced stage of degen-
eration compared to that of an early stage of degeneration.
There was a significant increase in the expression in the
NP region for all three proteins of the RANK/RANKL/
OPG system. RANKL differed from the other proteins in
that there was a significant increase in expression in all
three areas in advanced degenerated tissues compared to
those in the early degenerated tissues. The results of this
study suggest that the expression of the RANK/RANKL/
OPG system, especially RANKL, could be associated with
the progression of disc degeneration.
Conclusions
The results of this study demonstrated that the RANK/
RANKL/OPG system is present in the rat IVD, includ-
ing the CEP. Among the components of the RANK/
RANKL/OPG system, the gene expression of RANKL
was remarkably upregulated by treatment with IL-1β in
vitro by rat AF, NP and CEP cells. We can speculate
that the expression of RANKL is enhanced in the
proinflammatory-rich micro-environment of the degen-
erated IVD; thus, the RANK/RANKL/OPG system may
play a part in the complex molecular mechanism of
IVD degeneration by interactions with proinflammatory
cytokines. These molecular events would also be applic-
able for the pathogenesis of CEP degeneration. Add-
itionally, the significant increase in expression of the
RANK/RANKL/OPG system in the advanced stage of
degenerated human IVD tissues suggests that its ex-
pression would be associated with the progression of
disc degeneration.
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